NCT04063124View on ClinicalTrials.gov

Senolytic Therapy to Modulate Progression of Alzheimer's Disease

PHASE1/PHASE2CompletedINTERVENTIONAL

Enrollment

5

Participants

Timeline

Start Date

February 14, 2020

Primary Completion Date

December 10, 2021

Study Completion Date

January 30, 2023

Conditions

Alzheimer Disease

Interventions

DRUG

Dasatinib + Quercetin

Intermittent D+Q administered for 2 days on/14 days off for 12 weeks (6 cycles)

Trial Locations (1)

78229

Glenn Biggs Institute for Alzheimer's & Neurodegenerative Diseases, San Antonio

Sponsors

Collaborators (1)

All Listed Sponsors

collaborator

Mayo Clinic

OTHER

lead

The University of Texas Health Science Center at San Antonio

OTHER